Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Novo Nordisk, a leading global healthcare company, has announced the signing of a MoU with Lifera, a biopharmaceutical company owned by the Saudi sovereign wealth fund PIF (Public Investment Fund), to ...

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...